Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its CEO Ivor Elrifi increased his stake in the company through the purchase of 321,423 common shares on Nasdaq at $1.00 per share. Following the transaction, Elrifi holds 4,793,684 common shares.
Tiziana is developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody.